Geron appoints Alan Colowick as president, oncology
Geron Corporation announced the appointment of Alan B. Colowick, M.D., M.P.H., as president, oncology. In this newly created position, Dr. Colowick, 44, will manage the operational and strategic activities of the company's oncology programs. He will report to Dr. Thomas Okarma, Geron's president and CEO.
Prior to joining Geron, Dr. Colowick was the chief medical officer of Threshold Pharmaceuticals Inc., where he was responsible for all aspects of non-clinical and clinical development and manufacturing. Before this, he held a wide range of positions with Amgen Inc. Most recently, he served as vice president of European Medical Affairs.
Dr. Colowick was a clinical and research fellow in hematology-oncology at Harvard University and the Dana Farber Cancer Institute. He earned his M.P.H. at the Harvard School of Public Health and his M.D. at Stanford University School of Medicine.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Plant stress transformed into rapid tests for dangerous chemicals - Inexpensive method detects synthetic cannabinoids, banned pesticides
PTC Therapeutics and Genzyme Corporation Announce Preliminary Results from the Phase 2b Clinical Trial of Ataluren
Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
Indicia Production acquires METIS Biotechnologies

Immunodiagnostic Systems Ltd. (IDS Ltd.) - The Boldons, United Kingdom
